Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10383 in refractory or unexplained chronic cough
NCT06246565Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of HS-10383 in refractory chronic cough (RCC), sponsored by Hansoh Pharmaceutical Group. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
HS-10383
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT06246565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246565.